再生醫學的技術進步

Technological Advances in Regenerative Medicine

出版日期: 2024年08月20日 | 出版商:

Frost & Sullivan | 英文 55 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

顛覆性技術和競爭格局推動幹細胞治療研究的成長

再生醫學取得了巨大進步，多種幹細胞治療方法現已商業化。研究人員在幹細胞治療方面取得了顯著的技術發展，以克服與大規模生產和細胞品質相關的挑戰。由於iPS細胞研究的快速發展，幹細胞研究已集中在誘導性多功能幹細胞上，而不是間質幹細胞或造血幹細胞。技術平台的開發有助於改善整體幹細胞治療和選擇並降低整體成本。新興企業正在建立更新的細胞分離、表徵和篩檢流程，以確保恆定的細胞活力和保留。

產業公司擴大採用人工智慧和機器學習技術進行幹細胞成像、即時追蹤和進入新的疾病領域。除了罕見疾病外，幹細胞療法在治療腫瘤、神經系統疾病和心臟疾病也具有巨大潛力。私人投資和研究合作繼續推動幹細胞研究和開發，並支持各種疾病的臨床試驗管道。

本報告重點介紹了相關人員為幹細胞療法開發而設計的漸進技術改進和新平台，包括誘導性多功能幹細胞、間質幹細胞。

本研究解決的關鍵問題

幹細胞治療的現況和整體趨勢如何？哪些技術發展將改善幹細胞療法的研究和發展？哪些公司正在採用新技術平台來擴大幹細胞療法的研究和發展？幹細胞療法開發的投資和夥伴關係系統是怎麼樣的？

幹細胞療法開發的持續挑戰
幹細胞在再生醫學開發的臨床應用
iPS細胞治療的進展
間質幹細胞的開發
造血幹細胞的發育
hESC療法的發展
幹細胞療法開發商的整體技術實施
支持幹細胞開發的細胞製造平台
幹細胞選擇和表徵平台
幹細胞治療開發的人工智慧整合平台
用於幹細胞治療開發的人工智慧平台
幹細胞療法對各種疾病領域的影響

幹細胞研究、私人和公共投資的現狀

促進幹細胞治療的公共投資趨勢
近期私人投資趨勢推動幹細胞研究
幹細胞治療領域併購增加
擴大夥伴關係

成長機會宇宙

成長機會1：整合人工智慧和自動化以提高幹細胞的可擴展性
成長機會2：提升幹細胞品質的細胞工程與再程式化方法
成長機會3：先關注癌症，再關注罕見疾病

附錄

技術完備等級(TRL)：說明

下一步

成長機會的好處和影響
下一步
免責聲明

簡介目錄

Product Code: DAFE

Disruptive Technology and a Competitive Landscape Drive Growth in Stem Cell Therapy Research

Regenerative medicine has evolved significantly and today includes several commercialized stem cell therapies. Researchers have made notable technological developments in stem cell therapies to overcome challenges related to large-scale manufacturing and cell quality. Stem cell research is more focused on induced pluripotent stem cells than on mesenchymal and hematopoietic stem cells, a transition caused by the fast-paced developments in iPSC research. Developments in technology platform help improve overall stem cell therapy and selection and reduce overall costs. Emerging companies are establishing newer cell isolation, characterization, and screening processes to ensure constant cell viability and maintenance.

Industry players increasingly adopt artificial intelligence and machine learning technologies for stem cell imaging, real-time tracking, and entering new disease areas. Stem cell therapies have huge potential in treating oncology, neurological conditions, and cardiac conditions, apart from rare diseases. Private investments and collaborations continue to drive stem cell R&D and push the clinical trial pipelines across various diseases.

This report covers incremental technological improvements and the new platforms that stakeholders have designed for stem cell therapy developments in induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and human embryonic stem cells.

Key Questions This Study Addresses:

What is the current landscape of stem cell therapy, and what are the overall trends? What are the technology developments improving stem cell therapy R&D? Which companies are adopting new technology platforms to scale stem cell therapy R&D? What is the investment and partnership ecosystem in stem cell therapy development?

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Cell and Gene Therapy Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation

Growth Generator

Growth Drivers
Growth Restraints
Types of Common Stem Cells in Regenerative Medicine
Overall Trends in Stem Cell Therapy Development
Snapshot of the Regenerative Medicine Landscape

Growth Generator

Ongoing Challenges in the Development of Stem Cell Therapy
Highly Adopted Stem Cells in Clinical Use to Develop Regenerative Medicine
Developments in iPSC Therapies
Developments in MSCs
Developments in HSCs
Developments in hESC Therapies
Overall Technology Adoption by Stem Cell Therapy Developers
Cell Manufacturing Platforms Enabling Stem Cell Development
Stem Cell Selection and Characterization Platform
AI-integrated Platforms for Stem Cell Therapy Developments
AI Platforms for Stem Cell Therapy Development
Impact of Stem Cell Therapies in Various Diseases Areas

Stem Cell Research, Private and Public Investment Landscape

Public Investment Trends Driving Stem Cell Therapy Research
Recent Private Investments Driving Stem Cell Therapy Research
Growing M&As in Stem Cell Therapy
Growing Partnerships

Growth Opportunity Universe

Growth Opportunity 1: Integration of AI and Automation to Improve Stem Cell Scalability
Growth Opportunity 2: Cell Engineering and Reprogramming Methods to Improve Stem Cell Quality
Growth Opportunity 3: Focus on Cancer First and then on Rare Diseases